Innoviva Inc (NASDAQ: INVA)’s stock price has plunge by 0.14relation to previous closing price of 21.37. Nevertheless, the company has seen a 1.09% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-06-12 that WALTHAM, Mass. & GENEVA–(BUSINESS WIRE)–Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in.
Is It Worth Investing in Innoviva Inc (NASDAQ: INVA) Right Now?
Additionally, the 36-month beta value for INVA is 0.38. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for INVA is 62.00M and currently, short sellers hold a 14.96% ratio of that float. The average trading volume of INVA on June 13, 2025 was 899.84K shares.
INVA’s Market Performance
INVA’s stock has seen a 1.09% increase for the week, with a 17.20% rise in the past month and a 23.06% gain in the past quarter. The volatility ratio for the week is 0.39%, and the volatility levels for the past 30 days are at 1.00% for Innoviva Inc The simple moving average for the past 20 days is 7.37% for INVA’s stock, with a 14.12% simple moving average for the past 200 days.
Analysts’ Opinion of INVA
Many brokerage firms have already submitted their reports for INVA stocks, with Scotiabank repeating the rating for INVA by listing it as a “Sector Outperform.” The predicted price for INVA in the upcoming period, according to Scotiabank is $55 based on the research report published on March 07, 2025 of the current year 2025.
Goldman gave a rating of “Neutral” to INVA, setting the target price at $16 in the report published on July 20th of the previous year.
INVA Trading at 13.28% from the 50-Day Moving Average
After a stumble in the market that brought INVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.62% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INVA starting from DENNER ALEXANDER J, who sale 1,196,746 shares at the price of $17.52 back on Mar 06 ’25. After this action, DENNER ALEXANDER J now owns 5,658,705 shares of Innoviva Inc, valued at $20,964,237 using the latest closing price.
DENNER ALEXANDER J, the 10% Owner of Innoviva Inc, sale 270,374 shares at $17.63 during a trade that took place back on Mar 05 ’25, which means that DENNER ALEXANDER J is holding 6,855,451 shares at $4,766,126 based on the most recent closing price.
Stock Fundamentals for INVA
Current profitability levels for the company are sitting at:
- 0.28 for the present operating margin
- 0.86 for the gross margin
The net margin for Innoviva Inc stands at -0.16. The total capital return value is set at 0.1. Equity return is now at value -8.84, with -4.74 for asset returns.
Based on Innoviva Inc (INVA), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.44. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is 5.04.
Currently, EBITDA for the company is 99.45 million with net debt to EBITDA at 31.79. When we switch over and look at the enterprise to sales, we see a ratio of 3.95. The receivables turnover for the company is 4.79for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.48.
Conclusion
In conclusion, Innoviva Inc (INVA) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
